Compare Gilead Sciences, Inc. (GILD) vs Nucor Corporation (NUE) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
Gilead Sciences, Inc. vs Nucor Corporation — how do they compare? Gilead Sciences, Inc. trades at $151.28 (market cap $182.40B), while Nucor Corporation trades at $250.23 (market cap $55.84B). The key difference: Gilead Sciences, Inc. is far larger — about 3.3× Nucor Corporation's market cap, and Gilead Sciences, Inc. pays the higher dividend (2.23%). Which is the better fit depends on your goals — on Pluang, investors hold Gilead Sciences, Inc. for 111 Days and Nucor Corporation for 78 Days on average.
| GILD | NUE | |
|---|---|---|
Market Cap | $182.40B | $55.84B |
Volume | 4,469,821 | 848,835 |
Sector | Health | Basic Materials |
52-Week High | $155.80 | $274.74 |
52-Week Low | $116.74 | $131.78 |
Typical Hold Time | 111 Days | 78 Days |
Enterprise Value | $205.46B | $60.25B |
Dividend Yield | 2.23% | 0.91% |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Gilead Sciences (GILD) trades at $150.72, up 2.64% with a bullish technical signal and strong analyst support (65.5% buy ratings). Recent quarterly earnings have consistently beaten expectations, though Q2 2026 showed a significant loss. The company maintains robust operating cash flow ($10.02B in 2025) and is expanding HIV prevention access through new partnerships, positioning for growth despite a negative net income margin of -10.64%.
Outlook is cautiously optimistic with a consensus price target of $151.57, slightly above current levels. Key opportunities include pipeline advances in oncology and HIV treatments, while risks involve profitability volatility, high debt levels, and competitive pressures. The stock's valuation metrics suggest moderate pricing relative to earnings but elevated on sales and book value.
Nucor (NUE) trades at $250.98, up 1.84% on the day, showing resilience amid a mixed technical backdrop. Recent earnings have beaten expectations in Q1 and Q2 2026, though Q4 2025 was a miss. The company maintains a strong balance sheet with a debt-to-asset ratio of 20.23% for 2025, and analyst consensus is a Moderate Buy with a $266.88 price target. Revenue is projected to grow to $36.1B in 2026, with net income margin improving to 7.98%.
The outlook for NUE is cautiously optimistic, supported by earnings beats and a solid dividend history, but risks include competitive pressures from new steel capacity and volatile steel prices. The stock's current valuation metrics, such as a P/E of 19.64, appear reasonable relative to historical performance, offering potential upside if earnings guidance is met.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
Investor sentiment on Pluang
What Pluang investors did over the last 30 days
Investor sentiment on Pluang
What Pluang investors did over the last 30 days
Top news
Latest headlines on both assets
Top news
Latest headlines on both assets
About Gilead Sciences, Inc.
Gilead Sciences develops and markets therapies to treat life-threatening infectious diseases, with the core of its portfolio focused on HIV and hepatitis B and C. The acquisitions of Corus Pharma, Myogen, CV Therapeutics, Arresto Biosciences, and Calistoga have broadened this focus to include pulmonary and cardiovascular diseases and cancer. Gilead's acquisition of Pharmasset brought rights to hepatitis C drug Sovaldi, which is also part of combination drug Harvoni, and the Kite, Forty Seven, and Immunomedics acquisitions boost Gilead's exposure to cell therapy and noncell therapy in oncology.
Read more on GILD →About Nucor Corporation
Nucor Corp manufactures steel and steel products. The company also produces direct reduced iron for use in its steel mills. The operations include international trading and sales companies that buy and sell steel and steel products manufactured by the company and others. The operating business segments are: steel mills, steel products and raw materials, the steel mills segment derives maximum revenue.
Read more on NUE →
